US20110184282A1 - Self-deploying vascular occlusion device - Google Patents
Self-deploying vascular occlusion device Download PDFInfo
- Publication number
- US20110184282A1 US20110184282A1 US13/078,456 US201113078456A US2011184282A1 US 20110184282 A1 US20110184282 A1 US 20110184282A1 US 201113078456 A US201113078456 A US 201113078456A US 2011184282 A1 US2011184282 A1 US 2011184282A1
- Authority
- US
- United States
- Prior art keywords
- occluding member
- catheter
- distal end
- lumen
- vessel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/056—Transvascular endocardial electrode systems
- A61N1/057—Anchoring means; Means for fixing the head inside the heart
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/05—Electrodes for implantation or insertion into the body, e.g. heart electrode
- A61N1/056—Transvascular endocardial electrode systems
- A61N2001/0585—Coronary sinus electrodes
Definitions
- the present invention relates to an occlusion device for occluding or restricting the flow of blood in a vessel, and in particular to an occlusion device that self-deploys when subjected to blood flow in a vessel of a patient's vascular system.
- Cardiac function management systems are used to treat arrhythmias and other abnormal heart conditions.
- Such systems generally include cardiac leads, which are implanted in or about the heart, for delivering an electrical pulse to the cardiac muscle, for sensing electrical signals produced in the cardiac muscle, or for both delivering and sensing.
- a contrast agent in the vicinity of the coronary sinus and then to form an image of the coronary sinus and surrounding vasculature in order to identify an appropriate vessel for lead placement.
- a physician may perform a venogram procedure in which a radiopaque contrast agent is injected in the vicinity of the cardiac sinus, and then an X-ray image of the cardiac sinus is then taken.
- One difficulty physicians face when injecting a contrast agent in this manner is that retrograde blood flow tends to prematurely disperse the contrast agent such that the images of the desired blood vessels lack sufficient clarity for a physician to sub-select an appropriate vessel for lead placement.
- This contrast agent dispersion problem is particularly noticeable in the coronary sinus, which has a relatively large diameter and consequently passes a relatively high volume of blood.
- substantially transparent fluids e.g., saline or dextrose
- Such transparent fluids are used to provide an improved pathway or window for energy exposure, but may be carried away prematurely by blood flow.
- therapeutic agents for intravascular treatment of a condition.
- the therapeutic agent should be maintained in a specific location or region for at least a minimum time period.
- blood flow tends to carry the therapeutic agent away from the desired site prematurely.
- the present invention is a cardiac lead implantation system.
- the system includes an outer catheter having a proximal end and a distal end and an outer tubular wall which defines an outer lumen extending between the proximal and distal ends and an inner catheter having a proximal end and a distal end and an inner tubular wall which defines an inner lumen extending between the proximal and distal ends, the inner catheter being sized and shaped to pass through the outer lumen.
- a self-deploying occluding member is secured to the inner tubular wall. The occluding member is adapted to self-deploy from a compressed position when disposed within the outer lumen to an expanded position when positioned beyond the distal end of the outer catheter.
- the system further includes a cardiac lead for implantation in a coronary vessel, the cardiac lead being adapted to extend through either the inner or the outer lumen.
- the present invention is a method for delivering contrast agent to a coronary vessel in a patient.
- the method includes guiding an outer catheter into the vicinity of the coronary vessel, the outer catheter having a proximal end and a distal end and including an outer tubular wall defining an outer lumen extending between the proximal and distal ends.
- the occluding member is deployed to an expanded position by moving either the inner catheter or the outer catheter longitudinally such that the occluding member is moved beyond the distal end of the outer catheter and into the expanded position to restrict retrograde blood flow.
- a contrast agent is delivered to the coronary vessel while the occluding member is in the expanded position.
- the device includes a guide having proximal and distal ends and defining at least one lumen adapted to deliver a substance to the blood vessel, an occluding member including a frame coupled to the guide and a membrane attached to the frame, wherein the occluding member is adapted to actuate from a compressed position to an expanded position at least partially in response to blood flow in the blood vessel, and a tendon coupled to the guide and extending from the proximal end to near the distal end, the tendon having a tendon distal end coupled to the frame and adapted to at least partially actuate the occluding member.
- FIG. 1 shows a cardiac lead implanted in the vicinity of a patient's coronary sinus.
- FIGS. 2A-2C show a cardiac vascular occlusion system according to certain embodiments of the present invention.
- FIGS. 3A-3B show a cardiac vascular occlusion system according to another embodiment of the present invention.
- FIGS. 4A-4B show schematic views of a cardiac vascular occlusion system according to another embodiment of the present invention.
- FIGS. 5A-5B show a cardiac vascular occlusion system according to another embodiment of the present invention.
- FIG. 6 is a flowchart showing a method of using the cardiac vascular occlusion system according to one embodiment of the present invention.
- FIGS. 7A-7B shows a cardiac placement system according to one embodiment of the present invention implanted in the vicinity of a patient's coronary sinus.
- FIG. 1 is a schematic drawing of a cardiac rhythm management system 10 including a pulse generator 12 coupled to an lead 14 having a proximal end 16 and a distal end 18 .
- Distal portions of the lead 14 are disposed in the patient's heart 20 , which includes a right atrium 22 , a right ventricle 24 , a left atrium 26 , and a left ventricle 28 .
- the distal end 18 of the lead 14 is transvenously guided through the right atrium 22 , through the coronary sinus ostium 29 , and into a branch of the coronary sinus 31 or great cardiac vein 33 .
- the illustrated position of the lead 14 may be used for sensing, delivering pacing, and/or defibrillation energy to the left side of the heart 20 , for the treatment of arrhythmias or other cardiac disorders requiring therapy delivered to the left side of the heart 20 .
- FIGS. 2A-2C show a vascular occlusion system 30 according to various embodiments of the present invention.
- the vascular occlusion system 30 includes an outer catheter 32 , an inner catheter 34 , and an occluding member 36 .
- the outer catheter has a proximal end 38 , a distal end 40 , and a lumen 42 extending between the proximal end 38 and the distal end 40 .
- the inner catheter 34 also has a proximal end 44 , a distal end 46 and a lumen 48 extending between the proximal and distal ends 44 , 46 .
- the inner catheter 34 is sized and shaped to slide within the lumen 42 of the outer catheter 32 .
- the inner catheter 34 is a guidewire, which may or may not include an internal lumen.
- the occluding member 36 is shown in an expanded position in FIGS. 2A-2B , and in a compressed position within the lumen 42 of the outer catheter 32 in FIG. 2C .
- the occluding member 36 is attached to the inner catheter 34 and includes a frame portion 52 and a membrane portion 54 .
- the frame portion 52 is configured to allow expansion from the compressed position ( FIG. 2C ) to the expanded position ( FIGS. 2A-2B ) upon being deployed from the outer catheter 32 .
- the frame portion 52 may be formed in a variety of shapes and from a variety of conventional materials, including stainless steel, nitinol, and nickel/titanium alloys, as well as various shape memory alloys and polymers.
- the membrane portion 54 is attached to the frame portion 52 and is configured to unfold, inflate, or expand upon deployment from the outer catheter 32 depending on the material used to form the frame portion 52 and the membrane portion 54 .
- the membrane portion 54 may be formed from a relatively resilient material, including without limitation a variety of conventional polymeric materials as well as the materials used to form the frame portion 52 , such that the membrane portion 54 tends to block and/or re-circulate blood.
- the relatively flat occluding member 36 shown in FIG. 2A may tend to block fluid flow.
- the concave shape shown in FIG. 2B may tend to redirect and/or re-circulate blood flow in the opposite direction, thereby creating flow turbulences and/or eddies to impede normal blood flow.
- the membrane portion 54 may be formed from a more elastic polymer such that the membrane portion 54 tends to occlude by inflating.
- Suitable materials for the membrane portion 54 generally include substantially fluid impermeable materials such as silicone, polyurethane, and other biocompatible thermoplastic polymers.
- the membrane portion 54 may also be semi-permeable.
- the occluding member 36 may be formed from a unitary piece of material.
- the occluding member 36 self-expands after deployment from the outer catheter 32 .
- the occluding member 36 could be manually deployed through the use of strings, tendons, wires, or other members attached to the occluding member 36 and extending to the proximal ends of the outer and inner catheters 32 , 34 .
- the occluding member 36 could expand by inflating when exposed to fluid (e.g., blood) flow.
- FIGS. 3A-3B show perspective views of a vascular occlusion system 30 according to another embodiment of the present invention.
- FIG. 3A shows the system 30 in an expanded configuration
- FIG. 3B shows the system 30 in a compressed configuration.
- the system 30 includes an occluding member 60 , which includes a frame 62 and a membrane portion 64 .
- the frame 62 may have a shape and function similar to a conventional stent or embolic protection device, and includes struts 66 connected at each end to rings 68 , 70 .
- the frame 62 provides a scaffolding upon which the membrane portion 64 resides.
- the frame 62 may be self-expanding such that the occluding device 60 expands upon deploying from the outer catheter 32 .
- the frame 62 may be biased to a compressed position, but may expand in response to the force generated by the flow of fluid in the vessel against the membrane portion 64 .
- one or both of the rings 68 , 70 may slide relative to the inner catheter 34 to facilitate the expansion and/or compression of the struts 66 .
- ring 70 may slide, while ring 68 may remain fixed to the lead body.
- FIGS. 4A-4B show schematic views of a vascular occlusion system 30 according to another embodiment of the present invention.
- the system 30 includes an outer catheter 32 , an inner catheter 34 , and an occluding member 60 .
- the occluding member 60 which is coupled to the inner catheter 34 , has a frame 62 with rings 68 , 70 connected by struts 66 and a membrane portion 64 disposed over a portion of the frame 62 .
- the membrane portion 64 is disposed on a distal portion of the frame 62 (the left-hand side as shown in FIGS.
- the occluding member 60 is configured to occlude blood flowing in the same direction as the insertion path of the vascular occlusion system 30 (e.g., coronary artery applications).
- the membrane portion 64 is disposed on a proximal portion of the frame 62 , such that the occluding member 60 is configured to occlude blood flowing in the opposite direction of the insertion path (e.g., coronary vein applications).
- the occluding member 60 is held in a collapsed position (see FIG. 4B ) by the outer catheter 32 and is deployed by retracting the outer catheter 32 and allowing blood flow to impart a deploying force on the membrane portion 64 .
- the vascular occlusion system 30 includes a wire, tendon, or stylet 71 (or similar device), which is adapted to extend through or along the inner catheter 34 and couple to the ring 70 .
- the ring 70 is configured to slide along the inner catheter 34 to facilitate the expansion (see FIG. 4A ) or compression (see FIG. 4B ) of the occluding member 60 .
- the stylet 71 may be used to push or pull the ring 70 along the inner catheter 34 .
- the ring 68 is fixed, such that motion of the ring 70 proximally causes a radial expansion of the struts 66 , which in turn causes an expansion or opening of the membrane portion 64 . Once the membrane portion 64 opens slightly, blood flow in the vessel will impart a force on the membrane portion 64 causing full deployment.
- the ring 70 is fixed with respect to the inner catheter 34 and the stylet 71 is coupled to the ring 68 , which may slide distally to cause a radial expansion of the struts 66 .
- the inner catheter 34 includes a port or opening, which is disposed between the locations of the rings 68 , 70 while the occluding member 60 is in the expanded position (see FIG. 4A ). This opening may be used to inject a contrast agent or other substance through a lumen of the inner catheter 34 to within the occluded vessel.
- the stylet 71 may be located in the same lumen of the catheter 34 that is used to inject a contrast agent or other substance, or it may be located in a separate lumen.
- the catheter 34 includes two or more coaxial lumens, and the stylet 71 is located in an outer lumen located, for example, between two layers of the catheter 34 .
- the vascular occlusion system 30 does not include the outer catheter 32 , but instead includes only a single guide or catheter 34 .
- the tendon or stylet 71 is operable to cause axial movement of one of the rings 68 , 70 , with respect to the other.
- the occluding member 60 can be deployed by applying a force to the stylet 71 to cause one of the rings 68 , 70 to move toward the other, which causes a radial expansion of the struts 66 .
- occluding member 60 does not include the rings 68 , 70 .
- the stylet 71 is coupled to a portion of the frame 62 and the occluding member 60 is deployed by using the stylet 71 to effect an axial compression and corresponding radial expansion of the frame 62 .
- This radial expansion of the struts 66 causes an opening of the membrane portion 64 .
- Blood flow in the vessel then impacts the membrane portion 64 and causes full deployment.
- This deployment of the membrane portion 64 causes at least a partial occlusion of blood flow in the vessel.
- a contrast agent (or other substance) can then be injected into the vessel through a lumen of the catheter 34 .
- the occluding member 60 can be collapsed by using the stylet 71 to expand the distance between the rings 68 , 70 , which in turn causes the struts 66 and thus the membrane portion 64 to move adjacent the catheter 34 .
- the frame 62 is predisposed to hold the membrane portion 64 against the catheter 34 .
- FIGS. 5A-5B show perspective views of a vascular occlusion system 30 according to another embodiment of the present invention.
- the frame 62 again includes a plurality of struts 66 which form a stent-like shape.
- the distal end of the frame 62 is not crimped down or secured to the inner catheter 34 when expanded.
- the proximal end of the frame 62 is attached to the inner catheter 34 , for example, by a ring 68 , which may be movable or remain fixed relative to the inner catheter 34 .
- the frame self-expands, or expands under the force generated by blood flow against the membrane 64 , to occlude the desired vessel, and may be compressed by sliding outer catheter 32 distally over the occluding member 60 .
- the occluding member 36 or 60 may also be adjustable along various positions on the inner catheter 34 .
- the occluding member 36 or 60 is disposed proximally to the distal end of the inner catheter 34 .
- the occluding member 36 or 60 may be positioned between about 2 cm and about 5 cm from the distal end of the inner catheter 34 .
- One benefit of setting the occluding member 36 or 60 back from the distal end of the inner catheter 34 is that when a contrast agent is injected while the occluding member 36 or 60 is expanded, it may take longer for the contrast agent to flow past the occluding member 36 or 60 .
- the occluding member 36 or 60 may either partially or fully occlude the vessel depending on the diameter of the vessel as compared to the diameter of the occluding member 36 or 60 . In embodiments in which only partial occlusion occurs, some blood flow may continue past the occluding member 36 or 60 and through the vessel. Likewise, injected contrast agent may flow past the occluding member 36 or 60 such that vessels disposed proximally of the occluding member 36 or 60 may be imaged.
- One potential benefit of utilizing a self-expanding or flow-expanding occluding member 36 or 60 is that the risk of injuring, perforating, and/or bursting a vessel when the occluding member 36 or 60 expands is minimized as compared to a balloon-type member, which may run the risk of being overfilled during use.
- FIG. 6 is a flowchart showing a method of using the vascular occlusion system 30 shown in FIG. 2 according to one embodiment of the present invention.
- the outer catheter 32 is first directed into a patient's superior vena cava and through the opening of the coronary sinus 29 (block 80 ).
- the inner catheter 34 is then guided through the outer catheter 32 until the occluding member 36 is positioned just proximally of the distal end of the outer catheter 32 (block 82 ) as shown in FIG. 7A .
- the occluding member 36 is deployed distally out of the outer catheter 32 by relative movement between the outer catheter 32 and the inner catheter 34 (“ 84 ”).
- the occluding member 36 then expands as shown in FIG. 7B by one of the mechanisms described above in reference to specific embodiments of the present invention.
- the occluding member 36 limits retrograde blood flow (in the direction of the illustrated arrow) out of the coronary sinus.
- the occluding member 36 may reflect the blood flow to create counter-currents (e.g. turbulence or eddies), which in turn, limits retrograde blood flow.
- the occluding member does not necessarily completely prohibit fluid flow, but rather permits a limited volume of fluid to flow proximally of the occluding member. This may allow sufficient quantities of contrast agent to flow proximally of the occluding member to image vessels in that area. It may also reduce risks associated with over-pressurization of the coronary sinus.
- contrast agent may be injected distally of the occluding member 36 through the inner catheter 34 (block 86 ). As previously noted, the inner catheter 34 may extend several centimeters past the occluding member 36 to increase the dwell time of the contrast agent in the vessel 38 .
- a clinician may image the patient's great cardiac vein region using conventional imaging techniques. The clinician may then utilize the resulting images to sub-select a vessel for subsequent vascular occlusion (block 88 ). The occluding member 36 is then withdrawn back into the outer catheter 32 (or the outer catheter is forwardly over the occluding member 36 ) and into the compressed position (block 90 ).
- a cardiac lead 14 may be guided through either the inner catheter 32 or outer catheter 34 and implanted in the desired vessel (block 94 ) as shown in FIG. 1 .
- a guidewire may be placed in the sub-selected vessel and the lead 14 subsequently implanted. At times, it may become necessary or desirable for the clinician to perform a second imaging procedure after sub-selecting a particular vessel to further facilitate vascular occlusion.
- the occluding member of various embodiments of the present invention may be suitable for use in conjunction with catheters and/or other percutaneous devices that are placed in vessels (e.g. arteries, veins, arterioles, venules, capillaries) or other portions of the circulatory system in order to occlude blood flow.
- the occluding member may be positioned on a guidewire, IVUS Catheter, OCT catheter, or a photodynamic catheter to occlude blood flow during the infusion of a substantially transparent fluid (e.g. saline or dextrose), which replaces blood during the application of imaging or therapeutic energy (e.g. light, ultrasound, RF, electrical) to a vessel.
- a substantially transparent fluid e.g. saline or dextrose
- the occluding member may be utilized in conjunction with a catheter and/or guidewire to increase the residence time of an infused bioactive agent (e.g. cells, cell derivatives, pharmacological agents) in a vessel.
- an infused bioactive agent e.g. cells, cell derivatives, pharmacological agents
- An increased residence time may provide extended treatment at the desired location, and/or may localize the treatment at the desired vessel or tissue site.
Abstract
The present invention provides a cardiac vascular occlusion system which includes inner and outer guide catheters and an occluding member disposed on the inner catheter. The occluding member may be deployed from a compressed to an expanded position to limit retrograde blood flow in a body lumen. The occluding member may be used when injecting a contrast agent into the body lumen.
Description
- This application is a continuation application of U.S. patent application Ser. No. 12/237,121, filed Sep. 24, 2008, which is herein incorporated by reference in its entirety for all purposes.
- The present invention relates to an occlusion device for occluding or restricting the flow of blood in a vessel, and in particular to an occlusion device that self-deploys when subjected to blood flow in a vessel of a patient's vascular system.
- Cardiac function management systems are used to treat arrhythmias and other abnormal heart conditions. Such systems generally include cardiac leads, which are implanted in or about the heart, for delivering an electrical pulse to the cardiac muscle, for sensing electrical signals produced in the cardiac muscle, or for both delivering and sensing.
- During the cardiac lead placement procedure, it often becomes necessary and/or desirable to inject a contrast agent in the vicinity of the coronary sinus and then to form an image of the coronary sinus and surrounding vasculature in order to identify an appropriate vessel for lead placement. For example, a physician may perform a venogram procedure in which a radiopaque contrast agent is injected in the vicinity of the cardiac sinus, and then an X-ray image of the cardiac sinus is then taken. One difficulty physicians face when injecting a contrast agent in this manner is that retrograde blood flow tends to prematurely disperse the contrast agent such that the images of the desired blood vessels lack sufficient clarity for a physician to sub-select an appropriate vessel for lead placement. This contrast agent dispersion problem is particularly noticeable in the coronary sinus, which has a relatively large diameter and consequently passes a relatively high volume of blood.
- Physicians face similar difficulties when injecting substantially transparent fluids (e.g., saline or dextrose) prior to light or ultrasound imaging of the vessel, and/or prior to subjecting a vessel to photodynamic and/or RF/electrical therapy. Such transparent fluids are used to provide an improved pathway or window for energy exposure, but may be carried away prematurely by blood flow. Further difficulties are faced by physicians injecting therapeutic agents for intravascular treatment of a condition. Typically, the therapeutic agent should be maintained in a specific location or region for at least a minimum time period. However, blood flow tends to carry the therapeutic agent away from the desired site prematurely.
- There is a need in the art for a device adapted to occlude blood flow in a vessel to help maintain an injected substance at a target site in the vessel. There is a further need for a device which deploys readily and reliably.
- The present invention, according to one embodiment, is a cardiac lead implantation system. The system includes an outer catheter having a proximal end and a distal end and an outer tubular wall which defines an outer lumen extending between the proximal and distal ends and an inner catheter having a proximal end and a distal end and an inner tubular wall which defines an inner lumen extending between the proximal and distal ends, the inner catheter being sized and shaped to pass through the outer lumen. A self-deploying occluding member is secured to the inner tubular wall. The occluding member is adapted to self-deploy from a compressed position when disposed within the outer lumen to an expanded position when positioned beyond the distal end of the outer catheter. The system further includes a cardiac lead for implantation in a coronary vessel, the cardiac lead being adapted to extend through either the inner or the outer lumen.
- According to another embodiment, the present invention is a method for delivering contrast agent to a coronary vessel in a patient. The method includes guiding an outer catheter into the vicinity of the coronary vessel, the outer catheter having a proximal end and a distal end and including an outer tubular wall defining an outer lumen extending between the proximal and distal ends. It further includes guiding an inner catheter through the outer lumen and past the distal end of the outer catheter, the inner catheter having a proximal end and a distal end, and including an inner tubular wall defining an inner lumen extending between the proximal and distal ends, wherein the inner catheter further includes an occluding member secured to the inner tubular wall, the occluding member being retained in a compressed position when disposed within the outer lumen. The occluding member is deployed to an expanded position by moving either the inner catheter or the outer catheter longitudinally such that the occluding member is moved beyond the distal end of the outer catheter and into the expanded position to restrict retrograde blood flow. A contrast agent is delivered to the coronary vessel while the occluding member is in the expanded position.
- Another embodiment of the present invention is a device for occluding a blood vessel. The device includes a guide having proximal and distal ends and defining at least one lumen adapted to deliver a substance to the blood vessel, an occluding member including a frame coupled to the guide and a membrane attached to the frame, wherein the occluding member is adapted to actuate from a compressed position to an expanded position at least partially in response to blood flow in the blood vessel, and a tendon coupled to the guide and extending from the proximal end to near the distal end, the tendon having a tendon distal end coupled to the frame and adapted to at least partially actuate the occluding member.
- While multiple embodiments are disclosed, still other embodiments of the present invention will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative embodiments of the invention. As will be realized, the invention is capable of modifications in various obvious aspects, all without departing from the spirit and scope of the present invention. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not restrictive.
-
FIG. 1 shows a cardiac lead implanted in the vicinity of a patient's coronary sinus. -
FIGS. 2A-2C show a cardiac vascular occlusion system according to certain embodiments of the present invention. -
FIGS. 3A-3B show a cardiac vascular occlusion system according to another embodiment of the present invention. -
FIGS. 4A-4B show schematic views of a cardiac vascular occlusion system according to another embodiment of the present invention. -
FIGS. 5A-5B show a cardiac vascular occlusion system according to another embodiment of the present invention. -
FIG. 6 is a flowchart showing a method of using the cardiac vascular occlusion system according to one embodiment of the present invention. -
FIGS. 7A-7B shows a cardiac placement system according to one embodiment of the present invention implanted in the vicinity of a patient's coronary sinus. - While the invention is amenable to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and are described in detail below. The intention, however, is not to limit the invention to the particular embodiments described. On the contrary, the invention is intended to cover all modifications, equivalents, and alternatives falling within the scope of the invention as defined by the appended claims.
-
FIG. 1 is a schematic drawing of a cardiacrhythm management system 10 including apulse generator 12 coupled to anlead 14 having aproximal end 16 and a distal end 18. Distal portions of thelead 14 are disposed in the patient'sheart 20, which includes aright atrium 22, a right ventricle 24, aleft atrium 26, and a left ventricle 28. In the embodiment illustrated inFIG. 1 , the distal end 18 of thelead 14 is transvenously guided through theright atrium 22, through thecoronary sinus ostium 29, and into a branch of thecoronary sinus 31 or greatcardiac vein 33. The illustrated position of thelead 14 may be used for sensing, delivering pacing, and/or defibrillation energy to the left side of theheart 20, for the treatment of arrhythmias or other cardiac disorders requiring therapy delivered to the left side of theheart 20. -
FIGS. 2A-2C show avascular occlusion system 30 according to various embodiments of the present invention. Thevascular occlusion system 30 includes anouter catheter 32, aninner catheter 34, and anoccluding member 36. The outer catheter has aproximal end 38, adistal end 40, and alumen 42 extending between theproximal end 38 and thedistal end 40. Theinner catheter 34 also has aproximal end 44, adistal end 46 and alumen 48 extending between the proximal anddistal ends inner catheter 34 is sized and shaped to slide within thelumen 42 of theouter catheter 32. According to one embodiment, theinner catheter 34 is a guidewire, which may or may not include an internal lumen. - The
occluding member 36 is shown in an expanded position inFIGS. 2A-2B , and in a compressed position within thelumen 42 of theouter catheter 32 inFIG. 2C . The occludingmember 36 is attached to theinner catheter 34 and includes aframe portion 52 and amembrane portion 54. Theframe portion 52 is configured to allow expansion from the compressed position (FIG. 2C ) to the expanded position (FIGS. 2A-2B ) upon being deployed from theouter catheter 32. Theframe portion 52 may be formed in a variety of shapes and from a variety of conventional materials, including stainless steel, nitinol, and nickel/titanium alloys, as well as various shape memory alloys and polymers. - The
membrane portion 54 is attached to theframe portion 52 and is configured to unfold, inflate, or expand upon deployment from theouter catheter 32 depending on the material used to form theframe portion 52 and themembrane portion 54. In one embodiment, themembrane portion 54 may be formed from a relatively resilient material, including without limitation a variety of conventional polymeric materials as well as the materials used to form theframe portion 52, such that themembrane portion 54 tends to block and/or re-circulate blood. For example, the relatively flat occludingmember 36 shown inFIG. 2A may tend to block fluid flow. In contrast, the concave shape shown inFIG. 2B may tend to redirect and/or re-circulate blood flow in the opposite direction, thereby creating flow turbulences and/or eddies to impede normal blood flow. - In another embodiment, the
membrane portion 54 may be formed from a more elastic polymer such that themembrane portion 54 tends to occlude by inflating. Suitable materials for themembrane portion 54 generally include substantially fluid impermeable materials such as silicone, polyurethane, and other biocompatible thermoplastic polymers. Themembrane portion 54 may also be semi-permeable. In one embodiment, the occludingmember 36 may be formed from a unitary piece of material. - In one embodiment, the occluding
member 36 self-expands after deployment from theouter catheter 32. Alternatively, the occludingmember 36 could be manually deployed through the use of strings, tendons, wires, or other members attached to the occludingmember 36 and extending to the proximal ends of the outer andinner catheters member 36 could expand by inflating when exposed to fluid (e.g., blood) flow. -
FIGS. 3A-3B show perspective views of avascular occlusion system 30 according to another embodiment of the present invention.FIG. 3A shows thesystem 30 in an expanded configuration, andFIG. 3B shows thesystem 30 in a compressed configuration. As shown inFIGS. 3A-3B , thesystem 30 includes an occludingmember 60, which includes aframe 62 and amembrane portion 64. Theframe 62 may have a shape and function similar to a conventional stent or embolic protection device, and includesstruts 66 connected at each end torings frame 62 provides a scaffolding upon which themembrane portion 64 resides. - The
frame 62 may be self-expanding such that the occludingdevice 60 expands upon deploying from theouter catheter 32. Alternatively, theframe 62 may be biased to a compressed position, but may expand in response to the force generated by the flow of fluid in the vessel against themembrane portion 64. In either case, one or both of therings inner catheter 34 to facilitate the expansion and/or compression of thestruts 66. In a particular embodiment,ring 70 may slide, whilering 68 may remain fixed to the lead body. -
FIGS. 4A-4B show schematic views of avascular occlusion system 30 according to another embodiment of the present invention. As show inFIGS. 4A-4B , thesystem 30 includes anouter catheter 32, aninner catheter 34, and an occludingmember 60. The occludingmember 60, which is coupled to theinner catheter 34, has aframe 62 withrings struts 66 and amembrane portion 64 disposed over a portion of theframe 62. As shown, themembrane portion 64 is disposed on a distal portion of the frame 62 (the left-hand side as shown inFIGS. 4A and 4B ), such that the occludingmember 60 is configured to occlude blood flowing in the same direction as the insertion path of the vascular occlusion system 30 (e.g., coronary artery applications). According to another embodiment, themembrane portion 64 is disposed on a proximal portion of theframe 62, such that the occludingmember 60 is configured to occlude blood flowing in the opposite direction of the insertion path (e.g., coronary vein applications). In one embodiment, the occludingmember 60 is held in a collapsed position (seeFIG. 4B ) by theouter catheter 32 and is deployed by retracting theouter catheter 32 and allowing blood flow to impart a deploying force on themembrane portion 64. - In another embodiment, the
vascular occlusion system 30 includes a wire, tendon, or stylet 71 (or similar device), which is adapted to extend through or along theinner catheter 34 and couple to thering 70. In this embodiment, thering 70 is configured to slide along theinner catheter 34 to facilitate the expansion (seeFIG. 4A ) or compression (seeFIG. 4B ) of the occludingmember 60. Thestylet 71 may be used to push or pull thering 70 along theinner catheter 34. In this embodiment, thering 68 is fixed, such that motion of thering 70 proximally causes a radial expansion of thestruts 66, which in turn causes an expansion or opening of themembrane portion 64. Once themembrane portion 64 opens slightly, blood flow in the vessel will impart a force on themembrane portion 64 causing full deployment. - In one embodiment, the
ring 70 is fixed with respect to theinner catheter 34 and thestylet 71 is coupled to thering 68, which may slide distally to cause a radial expansion of thestruts 66. In one embodiment, theinner catheter 34 includes a port or opening, which is disposed between the locations of therings member 60 is in the expanded position (seeFIG. 4A ). This opening may be used to inject a contrast agent or other substance through a lumen of theinner catheter 34 to within the occluded vessel. Thestylet 71 may be located in the same lumen of thecatheter 34 that is used to inject a contrast agent or other substance, or it may be located in a separate lumen. In one embodiment, thecatheter 34 includes two or more coaxial lumens, and thestylet 71 is located in an outer lumen located, for example, between two layers of thecatheter 34. - In one embodiment, the
vascular occlusion system 30 does not include theouter catheter 32, but instead includes only a single guide orcatheter 34. In this embodiment, the tendon orstylet 71 is operable to cause axial movement of one of therings member 60 can be deployed by applying a force to thestylet 71 to cause one of therings struts 66. In another embodiment, occludingmember 60 does not include therings stylet 71 is coupled to a portion of theframe 62 and the occludingmember 60 is deployed by using thestylet 71 to effect an axial compression and corresponding radial expansion of theframe 62. - This radial expansion of the
struts 66 causes an opening of themembrane portion 64. Blood flow in the vessel then impacts themembrane portion 64 and causes full deployment. This deployment of themembrane portion 64 causes at least a partial occlusion of blood flow in the vessel. A contrast agent (or other substance) can then be injected into the vessel through a lumen of thecatheter 34. The occludingmember 60 can be collapsed by using thestylet 71 to expand the distance between therings struts 66 and thus themembrane portion 64 to move adjacent thecatheter 34. In one embodiment, theframe 62 is predisposed to hold themembrane portion 64 against thecatheter 34. -
FIGS. 5A-5B show perspective views of avascular occlusion system 30 according to another embodiment of the present invention. As shown inFIGS. 5A-5B , theframe 62 again includes a plurality ofstruts 66 which form a stent-like shape. In this embodiment, as compared to that ofFIGS. 3A-3B , the distal end of theframe 62 is not crimped down or secured to theinner catheter 34 when expanded. The proximal end of theframe 62 is attached to theinner catheter 34, for example, by aring 68, which may be movable or remain fixed relative to theinner catheter 34. In either case, the frame self-expands, or expands under the force generated by blood flow against themembrane 64, to occlude the desired vessel, and may be compressed by slidingouter catheter 32 distally over the occludingmember 60. - The occluding
member inner catheter 34. In one embodiment, the occludingmember inner catheter 34. For example, the occludingmember inner catheter 34. One benefit of setting the occludingmember inner catheter 34 is that when a contrast agent is injected while the occludingmember member - In the expanded configuration, the occluding
member member member member member occluding member member -
FIG. 6 is a flowchart showing a method of using thevascular occlusion system 30 shown inFIG. 2 according to one embodiment of the present invention. As show, theouter catheter 32 is first directed into a patient's superior vena cava and through the opening of the coronary sinus 29 (block 80). Theinner catheter 34 is then guided through theouter catheter 32 until the occludingmember 36 is positioned just proximally of the distal end of the outer catheter 32 (block 82) as shown inFIG. 7A . when a clinician decides to image thecoronary sinus 29 and surrounding vessels, the occludingmember 36 is deployed distally out of theouter catheter 32 by relative movement between theouter catheter 32 and the inner catheter 34 (“84”). The occludingmember 36 then expands as shown inFIG. 7B by one of the mechanisms described above in reference to specific embodiments of the present invention. - Upon expansion, the occluding
member 36 limits retrograde blood flow (in the direction of the illustrated arrow) out of the coronary sinus. In the illustrated embodiment, the occludingmember 36 may reflect the blood flow to create counter-currents (e.g. turbulence or eddies), which in turn, limits retrograde blood flow. - In one embodiment, the occluding member does not necessarily completely prohibit fluid flow, but rather permits a limited volume of fluid to flow proximally of the occluding member. This may allow sufficient quantities of contrast agent to flow proximally of the occluding member to image vessels in that area. It may also reduce risks associated with over-pressurization of the coronary sinus. After deploying the occluding
member 36, contrast agent may be injected distally of the occludingmember 36 through the inner catheter 34 (block 86). As previously noted, theinner catheter 34 may extend several centimeters past the occludingmember 36 to increase the dwell time of the contrast agent in thevessel 38. - During and/or after injecting the contrast agent into the
vessel 38, a clinician may image the patient's great cardiac vein region using conventional imaging techniques. The clinician may then utilize the resulting images to sub-select a vessel for subsequent vascular occlusion (block 88). The occludingmember 36 is then withdrawn back into the outer catheter 32 (or the outer catheter is forwardly over the occluding member 36) and into the compressed position (block 90). - After the
inner catheter 34 and/orouter catheter 32 is directed into the sub-selected vessel (block 92), acardiac lead 14 may be guided through either theinner catheter 32 orouter catheter 34 and implanted in the desired vessel (block 94) as shown inFIG. 1 . Alternatively, a guidewire may be placed in the sub-selected vessel and thelead 14 subsequently implanted. At times, it may become necessary or desirable for the clinician to perform a second imaging procedure after sub-selecting a particular vessel to further facilitate vascular occlusion. - Although certain Figures are directed to the use of occluding members to facilitate cardiac vascular occlusion, other applications of such occluding members are also within the scope of the present invention. Generally speaking, the occluding member of various embodiments of the present invention may be suitable for use in conjunction with catheters and/or other percutaneous devices that are placed in vessels (e.g. arteries, veins, arterioles, venules, capillaries) or other portions of the circulatory system in order to occlude blood flow. For example, the occluding member may be positioned on a guidewire, IVUS Catheter, OCT catheter, or a photodynamic catheter to occlude blood flow during the infusion of a substantially transparent fluid (e.g. saline or dextrose), which replaces blood during the application of imaging or therapeutic energy (e.g. light, ultrasound, RF, electrical) to a vessel.
- In another example, the occluding member may be utilized in conjunction with a catheter and/or guidewire to increase the residence time of an infused bioactive agent (e.g. cells, cell derivatives, pharmacological agents) in a vessel. An increased residence time may provide extended treatment at the desired location, and/or may localize the treatment at the desired vessel or tissue site.
- Various modifications and additions can be made to the exemplary embodiments discussed without departing from the scope of the present invention. For example, while the embodiments described above refer to particular features, the scope of this invention also includes embodiments having different combinations of features and embodiments that do not include all of the described features. Accordingly, the scope of the present invention is intended to embrace all such alternatives, modifications, and variations as fall within the scope of the claims, together with all equivalents thereof.
Claims (20)
1. A method for delivering contrast agent to a coronary vessel in a patient comprising:
guiding an outer catheter into the vicinity of the coronary vessel, the outer catheter having a proximal end, a distal end and an outer tubular wall defining an outer lumen extending between the proximal and distal ends;
guiding an inner catheter through the outer lumen, the inner catheter having a proximal end, a distal end, and an inner tubular wall defining an inner lumen extending between the proximal and distal ends, wherein the inner catheter further includes an occluding member secured to the inner tubular wall, the occluding member being retained in a compressed position when disposed within the outer lumen;
deploying the occluding member to an expanded position by moving either the inner catheter or the outer catheter longitudinally such that the occluding member is moved beyond the distal end of the outer catheter and into the expanded position to restrict retrograde blood flow; and
delivering a contrast agent to the coronary vessel while the occluding member is in the expanded position.
2. The method of claim 1 , wherein the distal end of the inner catheter is guided through the coronary sinus and distally of the distal end of the outer catheter.
3. The method of claim 1 , wherein the contrast agent is delivered to the body lumen site through a lumen in the inner or outer catheter.
4. The method of claim 1 , wherein deploying the occluding member comprises exposing the occluding member to blood flowing through the coronary vessel, the blood flow causing the occluding member to expand.
5. The method of claim 1 , wherein the occluding member further comprises a ring that is operably connected to a stylet, and deploying the occluding member comprises moving the stylet in an axial direction.
6. The method of claim 1 , wherein the occluding member has a flat shape configured to block blood flow.
7. The method of claim 1 , wherein the occluding member has a concave shape configured to redirect blood flow in an opposite direction.
8. The method of claim 1 , further comprising sub-selecting a vessel for cardiac lead placement.
9. The method of claim 8 , further comprising withdrawing the occluding member and directing the inner catheter into the sub-selected vessel.
10. The method of claim 9 , further comprising guiding a cardiac lead through the inner catheter and into the sub-selected vessel.
11. A method for delivering contrast agent to a coronary vessel in a patient comprising:
guiding an outer catheter into the vicinity of the coronary vessel, the outer catheter having a proximal end, a distal end and an outer tubular wall defining an outer lumen extending between the proximal and distal ends;
guiding an inner catheter through the outer lumen, the inner catheter having a proximal end, a distal end and an inner tubular wall defining an inner lumen extending between the proximal and distal ends, wherein the inner catheter further includes an inflatable occluding member secured to the inner tubular wall;
deploying the inflatable occluding member to an expanded position by inflating the inflatable occluding member such that the inflatable occluding member restricts retrograde blood flow; and
delivering a contrast agent to the coronary vessel while the inflatable occluding member is in the expanded position.
12. The method of claim 11 , further comprising guiding a cardiac lead through either the inner or outer lumen for implantation in the vicinity of the patient's heart.
13. The method of claim 11 , wherein the distal end of the inner catheter is guided through the coronary sinus and distally of the distal end of the outer catheter.
14. The method of claim 11 , wherein the contrast agent is delivered to the body lumen site through a lumen in the inner or outer catheter.
15. A device for occluding a blood vessel, the device comprising:
a guide having a proximal end, a distal end and at least one lumen extending therebetween adapted to deliver a substance to the blood vessel;
an occluding member including a frame coupled to the guide and a membrane attached to the frame, wherein the occluding member is adapted to actuate from a compressed position to an expanded position at least partially in response to blood flow in the blood vessel; and
a tendon coupled to the guide and extending from the proximal end to near the distal end, the tendon having a tendon distal end coupled to the frame and adapted to at least partially actuate the occluding member.
16. The device of claim 15 , wherein the tendon is disposed within the lumen or within a separate lumen in the guide.
17. The device of claim 15 , wherein the frame includes a first ring, a second ring, and a plurality of struts connecting the first and second rings, and further wherein the tendon distal end is coupled to one of the first and second rings.
18. The device of claim 17 , wherein the first ring is axially fixed with respect to the inner guide and the second ring is slidably coupled to the inner guide, and further wherein the tendon is coupled to the second ring.
19. The device of claim 15 , wherein the inner guide comprises a guidewire or a catheter.
20. The device of claim 15 , wherein the inner guide is selected from the group consisting of an intravascular ultrasound device, an optical coherence tomography device, a photodynamic therapy device and an ablation device.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/078,456 US20110184282A1 (en) | 2005-04-26 | 2011-04-01 | Self-deploying vascular occlusion device |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/115,594 US7935075B2 (en) | 2005-04-26 | 2005-04-26 | Self-deploying vascular occlusion device |
US12/237,121 US7908016B2 (en) | 2007-10-19 | 2008-09-24 | Fibrous electrode material |
US13/078,456 US20110184282A1 (en) | 2005-04-26 | 2011-04-01 | Self-deploying vascular occlusion device |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/115,594 Continuation US7935075B2 (en) | 2005-04-26 | 2005-04-26 | Self-deploying vascular occlusion device |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110184282A1 true US20110184282A1 (en) | 2011-07-28 |
Family
ID=37188042
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/115,594 Expired - Fee Related US7935075B2 (en) | 2005-04-26 | 2005-04-26 | Self-deploying vascular occlusion device |
US13/078,456 Abandoned US20110184282A1 (en) | 2005-04-26 | 2011-04-01 | Self-deploying vascular occlusion device |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/115,594 Expired - Fee Related US7935075B2 (en) | 2005-04-26 | 2005-04-26 | Self-deploying vascular occlusion device |
Country Status (1)
Country | Link |
---|---|
US (2) | US7935075B2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9990059B2 (en) | 2014-05-23 | 2018-06-05 | Microsoft Technology Licensing, Llc | Ink modes |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005067817A1 (en) | 2004-01-13 | 2005-07-28 | Remon Medical Technologies Ltd | Devices for fixing a sensor in a body lumen |
US9510930B2 (en) | 2008-10-22 | 2016-12-06 | Contego Medical, Llc | Angioplasty device with embolic filter |
US9707071B2 (en) * | 2004-11-24 | 2017-07-18 | Contego Medical Llc | Percutaneous transluminal angioplasty device with integral embolic filter |
US10390714B2 (en) * | 2005-01-12 | 2019-08-27 | Remon Medical Technologies, Ltd. | Devices for fixing a sensor in a lumen |
US7935075B2 (en) * | 2005-04-26 | 2011-05-03 | Cardiac Pacemakers, Inc. | Self-deploying vascular occlusion device |
US8060214B2 (en) | 2006-01-05 | 2011-11-15 | Cardiac Pacemakers, Inc. | Implantable medical device with inductive coil configurable for mechanical fixation |
US20070225750A1 (en) * | 2006-03-10 | 2007-09-27 | Brooke Ren | Embolic protection systems |
US8052731B2 (en) * | 2006-06-02 | 2011-11-08 | Cardiac Pacemakers, Inc. | Medical electrical lead with expandable fixation features |
US8676349B2 (en) | 2006-09-15 | 2014-03-18 | Cardiac Pacemakers, Inc. | Mechanism for releasably engaging an implantable medical device for implantation |
WO2008034077A2 (en) | 2006-09-15 | 2008-03-20 | Cardiac Pacemakers, Inc. | Anchor for an implantable sensor |
US8204599B2 (en) | 2007-05-02 | 2012-06-19 | Cardiac Pacemakers, Inc. | System for anchoring an implantable sensor in a vessel |
EP2162185B1 (en) | 2007-06-14 | 2015-07-01 | Cardiac Pacemakers, Inc. | Multi-element acoustic recharging system |
US8934987B2 (en) | 2008-07-15 | 2015-01-13 | Cardiac Pacemakers, Inc. | Implant assist apparatus for acoustically enabled implantable medical device |
EP2370138B1 (en) * | 2008-11-25 | 2020-12-30 | Edwards Lifesciences Corporation | Apparatus for in situ expansion of prosthetic device |
WO2010093489A2 (en) * | 2009-02-13 | 2010-08-19 | Cardiac Pacemakers, Inc. | Deployable sensor platform on the lead system of an implantable device |
US9820726B2 (en) * | 2009-08-24 | 2017-11-21 | St. Jude Medical Puerto Rico Llc | Polymer membrane locator with built-in stress relief structure |
US9539081B2 (en) | 2009-12-02 | 2017-01-10 | Surefire Medical, Inc. | Method of operating a microvalve protection device |
CA2837879C (en) * | 2011-06-03 | 2019-11-12 | Reverse Medical Corporation | Embolic implant and method of use |
EP2919845B1 (en) | 2012-11-15 | 2018-08-29 | Cardiac Pacemakers, Inc. | Guide catheter occlusion balloon with active inflation |
EP2967808A4 (en) * | 2013-03-15 | 2017-01-25 | Contego Medical, LLC | Percutaneous transluminal angioplasty device with integral embolic filter |
US10004512B2 (en) * | 2014-01-29 | 2018-06-26 | Cook Biotech Incorporated | Occlusion device and method of use thereof |
US9968740B2 (en) | 2014-03-25 | 2018-05-15 | Surefire Medical, Inc. | Closed tip dynamic microvalve protection device |
US9694201B2 (en) | 2014-04-24 | 2017-07-04 | Covidien Lp | Method of use of an embolic implant for radio-ablative treatment |
US20160106939A1 (en) * | 2014-10-20 | 2016-04-21 | Talal Sharaiha LLC | Expandable intubation assemblies |
US10292805B2 (en) | 2015-01-23 | 2019-05-21 | Contego Medical, Llc | Interventional device having an integrated embolic filter and associated methods |
US20160287839A1 (en) | 2015-03-31 | 2016-10-06 | Surefire Medical, Inc. | Apparatus and Method for Infusing an Immunotherapy Agent to a Solid Tumor for Treatment |
US9757574B2 (en) | 2015-05-11 | 2017-09-12 | Rainbow Medical Ltd. | Dual chamber transvenous pacemaker |
WO2017081561A1 (en) * | 2015-11-09 | 2017-05-18 | Revamp Medical Ltd. | Blood flow reducer for cardiovascular treatment |
US10780250B1 (en) | 2016-09-19 | 2020-09-22 | Surefire Medical, Inc. | System and method for selective pressure-controlled therapeutic delivery |
US11400263B1 (en) | 2016-09-19 | 2022-08-02 | Trisalus Life Sciences, Inc. | System and method for selective pressure-controlled therapeutic delivery |
WO2018156948A1 (en) * | 2017-02-23 | 2018-08-30 | Boston Scientific Scimed, Inc. | Medical drain device |
US10588636B2 (en) * | 2017-03-20 | 2020-03-17 | Surefire Medical, Inc. | Dynamic reconfigurable microvalve protection device |
US11020075B2 (en) | 2017-05-12 | 2021-06-01 | Cardiac Pacemakers, Inc. | Implantation of an active medical device using the internal thoracic vasculature |
US11850398B2 (en) | 2018-08-01 | 2023-12-26 | Trisalus Life Sciences, Inc. | Systems and methods for pressure-facilitated therapeutic agent delivery |
US11338117B2 (en) | 2018-10-08 | 2022-05-24 | Trisalus Life Sciences, Inc. | Implantable dual pathway therapeutic agent delivery port |
US20200383688A1 (en) * | 2019-06-04 | 2020-12-10 | Surefire Medical, Inc. | Atraumatic Occlusive System with Compartment for Measurement of Vascular Pressure Change |
US20210138239A1 (en) | 2019-09-25 | 2021-05-13 | Swift Sync, Llc | Transvenous Intracardiac Pacing Catheter |
Citations (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3592183A (en) * | 1969-05-27 | 1971-07-13 | David H Watkins | Heart assist method and apparatus |
US4407271A (en) * | 1980-07-28 | 1983-10-04 | Peter Schiff | Apparatus for left heart assist |
US5011488A (en) * | 1988-12-07 | 1991-04-30 | Robert Ginsburg | Thrombus extraction system |
US5775327A (en) * | 1995-06-07 | 1998-07-07 | Cardima, Inc. | Guiding catheter for the coronary sinus |
US5792094A (en) * | 1991-07-16 | 1998-08-11 | Heartport, Inc. | Method of delivering cardioplegic fluid to a patient's heart |
US5795325A (en) * | 1991-07-16 | 1998-08-18 | Heartport, Inc. | Methods and apparatus for anchoring an occluding member |
US5800457A (en) * | 1997-03-05 | 1998-09-01 | Gelbfish; Gary A. | Intravascular filter and associated methodology |
US5882329A (en) * | 1997-02-12 | 1999-03-16 | Prolifix Medical, Inc. | Apparatus and method for removing stenotic material from stents |
US5916193A (en) * | 1991-07-16 | 1999-06-29 | Heartport, Inc. | Endovascular cardiac venting catheter and method |
US5989281A (en) * | 1995-11-07 | 1999-11-23 | Embol-X, Inc. | Cannula with associated filter and methods of use during cardiac surgery |
US6001118A (en) * | 1997-03-06 | 1999-12-14 | Scimed Life Systems, Inc. | Distal protection device and method |
US6007557A (en) * | 1998-04-29 | 1999-12-28 | Embol-X, Inc. | Adjustable blood filtration system |
US6010522A (en) * | 1996-07-17 | 2000-01-04 | Embol-X, Inc. | Atherectomy device having trapping and excising means for removal of plaque from the aorta and other arteries |
US6014589A (en) * | 1997-11-12 | 2000-01-11 | Vnus Medical Technologies, Inc. | Catheter having expandable electrodes and adjustable stent |
US6090097A (en) * | 1996-05-14 | 2000-07-18 | Embol-X, Inc. | Aortic occluder with associated filter and methods of use during cardiac surgery |
US6113584A (en) * | 1998-02-13 | 2000-09-05 | Cardima, Inc. | Intraluminal delivery of tissue lysing medium |
US6245087B1 (en) * | 1999-08-03 | 2001-06-12 | Embol-X, Inc. | Variable expansion frame system for deploying medical devices and methods of use |
US6319242B1 (en) * | 1997-02-12 | 2001-11-20 | Prolifix Medical, Inc. | Apparatus and method for controlled removal of stenotic material from stents |
US20010056273A1 (en) * | 2000-06-20 | 2001-12-27 | Applied Medical Resources Corporation | Self-deploying catheter assembly |
US6368338B1 (en) * | 1999-03-05 | 2002-04-09 | Board Of Regents, The University Of Texas | Occlusion method and apparatus |
US20020072730A1 (en) * | 2000-10-12 | 2002-06-13 | Mcgill Scott A. | Methods and apparatus for protecting the proximal end of a medical device |
US6406471B1 (en) * | 1999-12-28 | 2002-06-18 | Embol-X, Inc. | Arterial filter with aspiration and methods of use |
US6423089B1 (en) * | 1996-12-03 | 2002-07-23 | Atrium Medical Corporation | Vascular endoprosthesis and method |
US6447505B2 (en) * | 1998-02-11 | 2002-09-10 | Cosman Company, Inc. | Balloon catheter method for intra-urethral radio-frequency urethral enlargement |
US20020161394A1 (en) * | 1997-09-26 | 2002-10-31 | Macoviak John A. | Aortic filter catheter |
US6485456B1 (en) * | 2000-02-01 | 2002-11-26 | Harold D. Kletschka | Embolic protection device having expandable trap |
US20020177835A1 (en) * | 1995-02-21 | 2002-11-28 | Zadini Filiberto P. | Catamenial device [intravaginal inflatable member] for blood leakage prevention |
US6575933B1 (en) * | 1998-11-30 | 2003-06-10 | Cryocath Technologies Inc. | Mechanical support for an expandable membrane |
US6612999B2 (en) * | 2001-12-06 | 2003-09-02 | Cardiac Pacemakers, Inc. | Balloon actuated guide catheter |
US6638294B1 (en) * | 2001-08-30 | 2003-10-28 | Advanced Cardiovascular Systems, Inc. | Self furling umbrella frame for carotid filter |
US6652555B1 (en) * | 1999-10-27 | 2003-11-25 | Atritech, Inc. | Barrier device for covering the ostium of left atrial appendage |
US6689150B1 (en) * | 1999-10-27 | 2004-02-10 | Atritech, Inc. | Filter apparatus for ostium of left atrial appendage |
US6709415B2 (en) * | 1997-09-23 | 2004-03-23 | Biosud S.A. | Intraluminal catheter with expandable tubular open-walled element |
US6743196B2 (en) * | 1999-03-01 | 2004-06-01 | Coaxia, Inc. | Partial aortic occlusion devices and methods for cerebral perfusion augmentation |
US20040116951A1 (en) * | 2002-11-13 | 2004-06-17 | Rosengart Todd K. | Apparatus and method for cutting a heart valve |
US20040172004A1 (en) * | 2001-07-17 | 2004-09-02 | Werner Mohl | Method and device for the intermitten occlusion of the coronary sinus |
US20050015048A1 (en) * | 2003-03-12 | 2005-01-20 | Chiu Jessica G. | Infusion treatment agents, catheters, filter devices, and occlusion devices, and use thereof |
US20050043678A1 (en) * | 2003-08-20 | 2005-02-24 | Toby Freyman | Medical device with drug delivery member |
US20050101902A1 (en) * | 2003-02-25 | 2005-05-12 | The Cleveland Clinic Foundation | Apparatus and method for auto-retroperfusion of a coronary vein |
US6949122B2 (en) * | 2001-11-01 | 2005-09-27 | Cardiac Dimensions, Inc. | Focused compression mitral valve device and method |
US7066904B2 (en) * | 1990-12-28 | 2006-06-27 | Boston Scientific Scimed, Inc. | Triggered release hydrogel drug delivery system |
US20060173490A1 (en) * | 2005-02-01 | 2006-08-03 | Boston Scientific Scimed, Inc. | Filter system and method |
US20060175490A1 (en) * | 2003-08-07 | 2006-08-10 | Musco Corporation | Enclosure box attachment apparatus, system, and method |
US20060241735A1 (en) * | 2005-04-26 | 2006-10-26 | Cardiac Pacemakers, Inc. | Self-deploying vascular occlusion device |
US7232452B2 (en) * | 2002-07-12 | 2007-06-19 | Ev3 Inc. | Device to create proximal stasis |
US7374560B2 (en) * | 2001-05-01 | 2008-05-20 | St. Jude Medical, Cardiology Division, Inc. | Emboli protection devices and related methods of use |
US7503904B2 (en) * | 2002-04-25 | 2009-03-17 | Cardiac Pacemakers, Inc. | Dual balloon telescoping guiding catheter |
US7585309B2 (en) * | 2002-05-16 | 2009-09-08 | Boston Scientific Scimed, Inc. | Aortic filter |
US7713282B2 (en) * | 1998-11-06 | 2010-05-11 | Atritech, Inc. | Detachable atrial appendage occlusion balloon |
US7713281B2 (en) * | 2003-10-03 | 2010-05-11 | Medtronic, Inc. | Expandable guide sheath and apparatus and methods for making them |
-
2005
- 2005-04-26 US US11/115,594 patent/US7935075B2/en not_active Expired - Fee Related
-
2011
- 2011-04-01 US US13/078,456 patent/US20110184282A1/en not_active Abandoned
Patent Citations (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3592183A (en) * | 1969-05-27 | 1971-07-13 | David H Watkins | Heart assist method and apparatus |
US4407271A (en) * | 1980-07-28 | 1983-10-04 | Peter Schiff | Apparatus for left heart assist |
US5011488A (en) * | 1988-12-07 | 1991-04-30 | Robert Ginsburg | Thrombus extraction system |
US7066904B2 (en) * | 1990-12-28 | 2006-06-27 | Boston Scientific Scimed, Inc. | Triggered release hydrogel drug delivery system |
US5916193A (en) * | 1991-07-16 | 1999-06-29 | Heartport, Inc. | Endovascular cardiac venting catheter and method |
US5792094A (en) * | 1991-07-16 | 1998-08-11 | Heartport, Inc. | Method of delivering cardioplegic fluid to a patient's heart |
US5795325A (en) * | 1991-07-16 | 1998-08-18 | Heartport, Inc. | Methods and apparatus for anchoring an occluding member |
US20020177835A1 (en) * | 1995-02-21 | 2002-11-28 | Zadini Filiberto P. | Catamenial device [intravaginal inflatable member] for blood leakage prevention |
US5775327A (en) * | 1995-06-07 | 1998-07-07 | Cardima, Inc. | Guiding catheter for the coronary sinus |
US5989281A (en) * | 1995-11-07 | 1999-11-23 | Embol-X, Inc. | Cannula with associated filter and methods of use during cardiac surgery |
US6090097A (en) * | 1996-05-14 | 2000-07-18 | Embol-X, Inc. | Aortic occluder with associated filter and methods of use during cardiac surgery |
US6231544B1 (en) * | 1996-05-14 | 2001-05-15 | Embol-X, Inc. | Cardioplegia balloon cannula |
US6010522A (en) * | 1996-07-17 | 2000-01-04 | Embol-X, Inc. | Atherectomy device having trapping and excising means for removal of plaque from the aorta and other arteries |
US6423089B1 (en) * | 1996-12-03 | 2002-07-23 | Atrium Medical Corporation | Vascular endoprosthesis and method |
US5882329A (en) * | 1997-02-12 | 1999-03-16 | Prolifix Medical, Inc. | Apparatus and method for removing stenotic material from stents |
US6319242B1 (en) * | 1997-02-12 | 2001-11-20 | Prolifix Medical, Inc. | Apparatus and method for controlled removal of stenotic material from stents |
US5800457A (en) * | 1997-03-05 | 1998-09-01 | Gelbfish; Gary A. | Intravascular filter and associated methodology |
US6001118A (en) * | 1997-03-06 | 1999-12-14 | Scimed Life Systems, Inc. | Distal protection device and method |
US6709415B2 (en) * | 1997-09-23 | 2004-03-23 | Biosud S.A. | Intraluminal catheter with expandable tubular open-walled element |
US20020161394A1 (en) * | 1997-09-26 | 2002-10-31 | Macoviak John A. | Aortic filter catheter |
US6014589A (en) * | 1997-11-12 | 2000-01-11 | Vnus Medical Technologies, Inc. | Catheter having expandable electrodes and adjustable stent |
US6447505B2 (en) * | 1998-02-11 | 2002-09-10 | Cosman Company, Inc. | Balloon catheter method for intra-urethral radio-frequency urethral enlargement |
US6113584A (en) * | 1998-02-13 | 2000-09-05 | Cardima, Inc. | Intraluminal delivery of tissue lysing medium |
US6007557A (en) * | 1998-04-29 | 1999-12-28 | Embol-X, Inc. | Adjustable blood filtration system |
US7713282B2 (en) * | 1998-11-06 | 2010-05-11 | Atritech, Inc. | Detachable atrial appendage occlusion balloon |
US6575933B1 (en) * | 1998-11-30 | 2003-06-10 | Cryocath Technologies Inc. | Mechanical support for an expandable membrane |
US6767345B2 (en) * | 1999-03-01 | 2004-07-27 | Coaxia, Inc. | Partial aortic occlusion devices and methods for renal and coronary perfusion augmentation |
US6743196B2 (en) * | 1999-03-01 | 2004-06-01 | Coaxia, Inc. | Partial aortic occlusion devices and methods for cerebral perfusion augmentation |
US6368338B1 (en) * | 1999-03-05 | 2002-04-09 | Board Of Regents, The University Of Texas | Occlusion method and apparatus |
US6245087B1 (en) * | 1999-08-03 | 2001-06-12 | Embol-X, Inc. | Variable expansion frame system for deploying medical devices and methods of use |
US6652555B1 (en) * | 1999-10-27 | 2003-11-25 | Atritech, Inc. | Barrier device for covering the ostium of left atrial appendage |
US6689150B1 (en) * | 1999-10-27 | 2004-02-10 | Atritech, Inc. | Filter apparatus for ostium of left atrial appendage |
US6406471B1 (en) * | 1999-12-28 | 2002-06-18 | Embol-X, Inc. | Arterial filter with aspiration and methods of use |
US6723085B2 (en) * | 1999-12-28 | 2004-04-20 | Edwards Lifesciences Corporation | Arterial filter with aspiration and methods of use |
US6485456B1 (en) * | 2000-02-01 | 2002-11-26 | Harold D. Kletschka | Embolic protection device having expandable trap |
US6589208B2 (en) * | 2000-06-20 | 2003-07-08 | Applied Medical Resources Corporation | Self-deploying catheter assembly |
US20010056273A1 (en) * | 2000-06-20 | 2001-12-27 | Applied Medical Resources Corporation | Self-deploying catheter assembly |
US20020072730A1 (en) * | 2000-10-12 | 2002-06-13 | Mcgill Scott A. | Methods and apparatus for protecting the proximal end of a medical device |
US7374560B2 (en) * | 2001-05-01 | 2008-05-20 | St. Jude Medical, Cardiology Division, Inc. | Emboli protection devices and related methods of use |
US20040172004A1 (en) * | 2001-07-17 | 2004-09-02 | Werner Mohl | Method and device for the intermitten occlusion of the coronary sinus |
US6638294B1 (en) * | 2001-08-30 | 2003-10-28 | Advanced Cardiovascular Systems, Inc. | Self furling umbrella frame for carotid filter |
US6949122B2 (en) * | 2001-11-01 | 2005-09-27 | Cardiac Dimensions, Inc. | Focused compression mitral valve device and method |
US6612999B2 (en) * | 2001-12-06 | 2003-09-02 | Cardiac Pacemakers, Inc. | Balloon actuated guide catheter |
US7503904B2 (en) * | 2002-04-25 | 2009-03-17 | Cardiac Pacemakers, Inc. | Dual balloon telescoping guiding catheter |
US7585309B2 (en) * | 2002-05-16 | 2009-09-08 | Boston Scientific Scimed, Inc. | Aortic filter |
US7232452B2 (en) * | 2002-07-12 | 2007-06-19 | Ev3 Inc. | Device to create proximal stasis |
US20040116951A1 (en) * | 2002-11-13 | 2004-06-17 | Rosengart Todd K. | Apparatus and method for cutting a heart valve |
US20050101902A1 (en) * | 2003-02-25 | 2005-05-12 | The Cleveland Clinic Foundation | Apparatus and method for auto-retroperfusion of a coronary vein |
US20050015048A1 (en) * | 2003-03-12 | 2005-01-20 | Chiu Jessica G. | Infusion treatment agents, catheters, filter devices, and occlusion devices, and use thereof |
US20060175490A1 (en) * | 2003-08-07 | 2006-08-10 | Musco Corporation | Enclosure box attachment apparatus, system, and method |
US20050043678A1 (en) * | 2003-08-20 | 2005-02-24 | Toby Freyman | Medical device with drug delivery member |
US7713281B2 (en) * | 2003-10-03 | 2010-05-11 | Medtronic, Inc. | Expandable guide sheath and apparatus and methods for making them |
US20060173490A1 (en) * | 2005-02-01 | 2006-08-03 | Boston Scientific Scimed, Inc. | Filter system and method |
US20060241735A1 (en) * | 2005-04-26 | 2006-10-26 | Cardiac Pacemakers, Inc. | Self-deploying vascular occlusion device |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9990059B2 (en) | 2014-05-23 | 2018-06-05 | Microsoft Technology Licensing, Llc | Ink modes |
US10275050B2 (en) | 2014-05-23 | 2019-04-30 | Microsoft Technology Licensing, Llc | Ink for a shared interactive space |
Also Published As
Publication number | Publication date |
---|---|
US7935075B2 (en) | 2011-05-03 |
US20060241735A1 (en) | 2006-10-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7935075B2 (en) | Self-deploying vascular occlusion device | |
US10842630B2 (en) | Methods of reducing regurgitation through an atrioventricular heart valve | |
EP3672532B1 (en) | Implantable cardiac pacing system | |
US11253698B2 (en) | Method for positioning terminal end of pacemaker lead, which has passed through coronary sinus, in interventricular septum | |
US9440054B2 (en) | Expandable transapical sheath and method of use | |
US8728153B2 (en) | Expandable transapical sheath and method of use | |
JP5260317B2 (en) | Blood vessel repair device | |
CN105682565B (en) | Right ventricular outflow line in bicuspid valve cerclage annuloplasty captures (RWC) system | |
CA2320826A1 (en) | Implantable cardiac lead with multiple shape memory polymer structures | |
JP2021519198A (en) | Assembly for placement of cardiac, aortic, or arterial implants with stimulation assistance with peripheral veins or arterial catheters | |
US20180154123A1 (en) | Implants and systems for electrically isolating one or more pulminary veins | |
JP2010516404A (en) | Expandable member for intravenous lead fixation | |
WO2010121192A1 (en) | Devices, systems, and methods for the prevention of stroke | |
US9656030B1 (en) | System for the injection of cells and/or biologically active materials into coronary arteries for therapeutic purposes | |
CN109621199A (en) | Electrode cable | |
IL292931A (en) | Transcatheter medical implant delivery | |
US20210045879A1 (en) | Cardiac annuloplasty procedures, related devices and methods | |
US20170281910A1 (en) | Guidewire device with deployable distal end portion, systems and methods thereof | |
CN109789255A (en) | For deliver vivo devices through conduit device and system | |
WO2024076579A1 (en) | Delivery device for confirming tissue capture of a shunt device | |
JP2024500417A (en) | flexible shunt implant | |
WO2024076578A1 (en) | Devices and methods for confirming tissue capture for a shunt device | |
CN109621198A (en) | The fixation device of medical device and its slender bodies Medical Devices | |
CN117545434A (en) | Implant and contrast agent delivery using a stagnation device | |
WO2023244186A1 (en) | Device for stabilizing patients in mitral valve regurgitation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |